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WHAT THIS PAPER ADDS?
 The surgical management of acute type A aortic dissection is evolving. This paper describes how endovascular solutions are likely to
improve outcomes in this challenging pathology. It reports the world experience to date and the speciﬁc challenges that remain to
the pioneers of endovascular therapy in the proximal aorta.a r t i c l e i n f o
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Proximal acute aortic dissection [type A] remains a disease with a poor prognosis. High peri-operative
open surgical mortality [up to 30%] and a signiﬁcant turn-down rate [up to 40%] substantiate the
bleak prospects for patients with this disease. Thoracic endovascular stent grafting has revolutionized
the treatment of distal [type B] acute aortic dissection. Endovascular surgeons are now looking to
improve the treatment of type A dissection by offering endovascular techniques to supplement
conventional surgical therapy. Less invasive endovascular therapy, obviates the need for sternotomy and
cardiopulmonary bypass, may reduce perioperative morbidity and offers a solution for those patients
declined conventional intervention due to co-morbidity or severe complications of the disease. Thoracic
stent grafting in the ascending aorta presents speciﬁc challenges due to proximity to the aortic valve,
navigation over the steep aortic arch and pulsatile aortic movement. Endovascular surgeons have treated
type A dissection off-license using aortic cuffs and stents designed for infra-renal aortic surgery. Now
grafts speciﬁcally designed for treating type A dissection are being developed and deployed under trial
[compassionate license] in patients deemed unﬁt for open surgery. This paper explores how endovas-
cular solutions may ﬁt into the future care of patients with acute type A dissection.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Type A acute aortic dissection [TAAD] is a catastrophic arterial
insult, which requires emergency cardiac surgical intervention.
Although surgical results have improved with superior grafts and
compatible suture materials, enhanced cardiopulmonary bypass,
cerebral protection, biologic glue and tailored postoperative
surveillance, overall in-hospital mortality remains as high as 30%.1
This statistic also fails to account for the considerable proportion of
patients (up to 40%) turned-down for operative intervention due to
co-morbidity or haemodynamic instability.2 The in-hospital
mortality for patients managed medically is also dismal (59% die
without leaving hospital).3tions on this paper, please go
: þ44 2087253495.
.
ciety for Vascular Surgery. PublishEndovascular solutions have become the preferredmanagement
of many complex aortic diseases involving the aortic arch and
descending thoracic aorta. Thoracic endografting has an estab-
lished role in acute complicated type B aortic dissection super-
seding primary open surgery. The ascending aorta represents the
new endovascular frontier,4 and clearly there is a requirement for
improved outcomes in TAAD. In this paper the possible role of
endovascular solutions to TAAD is explored.
Epidemiology
The reported estimates of thoracic aortic dissection [TAD] are
2.9e4.3 cases per 100,000 persons per year. Approximately two-
thirds of TADs involve the ascending aorta [Stanford type A].5 The
incidence appears to be rising, although this may simply be
a function of improved diagnostic imaging. TAAD is more com-
mon inmen, with an average age at onset of 63 years.2 The principle
risk factors are hypertension, aortic dilatation, congenitaled by Elsevier Ltd. All rights reserved.
Figure 1. Proposed suitability for a wholly endovascular solution to TAAD [STJ ¼ Sino-
tubular junction, A > 20 mm, B < 38 mm, C < 42 mm].
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[e.g. Marfan’s]. It appears likely that the incidence of TAAD will
increase as emergency departments utilise more cross sectional
imaging and patients are more rigorously investigated.
Current Gold Standard
Open surgical repair remains the gold standard treatment TAAD.
Surgery necessitates replacement of the ascending aorta some-
times requiring hypothermic circulatory arrest. The goals of repair
are to resect the primary intimal tear, resect and repair the
ascending aorta, achieve occlusion of the false lumen, restore aortic
valve competence and limit dissection downstream. Most patients
do not require aortic valve replacement or coronary re-
implantation, although this is required in 10e20% of cases.6 If the
tear has extended into the arch, the replacement of the arch and
great vessel re-implantation is required. Risk models have explored
factors associated with outcome. Independent preoperative
predictors of mortality include advancing age, prior cardiac surgery,
hypotension on presentation, neurological deﬁcit, and myocardial
ischaemia.7 Patients continue to be turned-down for life-saving
surgery when the risks of surgery outweigh the beneﬁts.
The natural history of the dissected aorta distal to the replaced
ascending can be one towards progressive enlargement despite
hemiarch replacement. This can lead to the need for re-operation in
up to one third of cases. Rigorous anti-hypertensive therapy and
life-long imaging is mandated in all cases following surgery.8 When
re-operation is indicated it often necessitates complex hybrid
endovascular solutions or high-risk thoracoabdominal surgery.
The Need for an Endovascular Solution?
Thoracic endovascular repair [TEVR] of complicated type B
aortic dissections [TBAD] has revolutionised the management of
this disease.9e11 The reduced physiological insult associated with
this technique has transformed the perioperative outcomes for
TBAD.12 Experience gained from TEVR for TBAD and the ever
increasing complexity of aortic disease treated endovascularly has
led a natural progression around the aortic arch. This is driven by
the poor outcomes associated with patients who cannot be treated
surgically and advances in understanding of endovascular
solutions.
The principle behind endovascular treatment of TAAD, as with
TBAD, is closure of the primary entry tear in the aorta. This
preserves true luminal blood ﬂow, encourages false lumen
thrombosis and allows the vessel to remodel.13 The rules of appli-
cability are the same as for all endovascular procedures; it is the
challenges that increase as endovascular surgeons migrate around
the arch, with greater potential for neurological and procedural
complications, proximity to the aortic valve and coronary ostia and
increased mobility of the aorta adjacent to the left ventricle.
Morphological Suitability
Endovascular suitability is dependent on adequate access
vessels, an appropriate location and length of the proximal and
distal landing zones, and luminal diameter compatible with avail-
able stent-grafts. In acute dissection additional exclusions to
endovascular repair include disturbed aortic valve function and
prior coronary revascularisation. The principle determinant of
suitability is the location of the primary proximal entry tear. This
must lie a minimum of 20 mm distal to the sinotubular junction to
allow stent coverage of the ﬂap whilst maintaining coronary blood
ﬂow. [Fig. 1] Themean distance, representing the safe landing zone,from sinotubular junction to innominate artery ostia is reported to
be 63.4  10.2 mm.14
Two studies have explored the feasibility of endovascular repair
of TAAD based purely on cross-sectional imaging. They report that,
based on current device designs 32e50% of patients currently
undergoing open repair for TAAD could potentially be candidates
for endovascular repair.15,16 [Table 1]Speciﬁc Challenges and Solutions
The anatomical and physiological challenges to endovascular
therapy of the ascending aorta remain formidable. They include
proximal graft ﬁxation close to the aortic valve and coronary ostia
and a distal landing zone that may impinge on the innominate
artery. The steep curvature of the distal ascending aorta and the
sizing discrepancies found in acute pathology highlight the
requirement for pathology-speciﬁc grafts. The haemodynamic
forces in the ascending aorta resist accurate graft deployment,
whilst the distal cone of current grafts prohibits deployment close
to the aortic valve. Accurate device control and deployment is
hindered by loss of torque control through tortuous iliac vessels
into the 270 aortic arch.
None of these challenges is insurmountable. Short large diam-
eter stents have been developed to ﬁt the ascending aortic
anatomy. Precise deployment in the tortuous and gothic-arched
aorta can be facilitated using stiff buddy wires or externalised
transeptal guidewire.17 Devices designed for ascending arch
pathology are longer than standard thoracic stents due to the
distance from the groin access site. They incorporate a shorter nose
cone to limit cardiac trauma at deployment.
As with all endovascular procedures endoleaks are the Achilles
heal. The short coverage means only proximal and distal type 1
leaks are relevant and represent treatment failure. This highlights
the advantages of devices made-for-purpose; designed to sit in the
ascending aorta, and appose the aortic wall.
Table 1
Proposed anatomical suitability criteria for endovascular treatment of TAAD.
Entry tear distal to sinotubular junction
Proximal and distal landing zone length >20 mm
Proximal landing zone diameter <38 mm
No aortic valve involvement
Absence of coronary grafts originating from ascending aorta
Adequate iliofemoral access vessels [24Fr]
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Meticulous planning is essential. ECG-gated contrast enhanced
CT images, to minimise motion artefact, should be examined on
dedicated vascular workstations. All measurements should be
based on centreline-of-ﬂow reconstructions. Preoperative trans-
oesophageal echocardiography [TOE] is essential to detect aortic
valve insufﬁciency or regurgitation. This investigation may also
allow accurate measurement of distance between dissection entry
tear and coronary ostia. TOE is used to evidence the presence of
pericardial effusions and cardiac tamponade which would further
exclude the patient from an endovascular solution.18 Grafts are
over-sized 5e10% relative to the native true lumen at the site of the
proximal seal zone to minimise aortic trauma. Endovascular
surgery should be performed under general anaesthesia. Accurate
deployment requires complete cardiac standstill, this should be
induced by overdrive pacing using a temporary cardiac pacing wire.
Serial angiography is performed to ensure accurate deployment
and patency of the coronary arteries and supra-aortic trunks.
Ballooning of the endograft is not recommended.Particular Risks
There are additive risks when operating further round the aortic
arch, particularly with the increased instrumentation, requirement
for reduced systemic blood pressure at deployment and proximity
to the aortic valve.19 Lessons have been learned from the trans-
catheter aortic valve implantation [TAVI] experience. Stroke is
perhaps the most worrisome complication and is generally
procedure-related and embolic. The risks increase as the procedure
progresses around the aortic arch.20 Stroke may occur as a conse-
quence of instrumentation around the diseased aortic arch or
extension of the dissection into the supra-aortic branches. In the
TAVI population trials of embolic-protection devices (Embrella
embolic deﬂector system, Edwards Lifesciences, Irvine, CA, USA)
are being considered;21,22 it is likely these results will translate to
endovascular strategies for TAAD. The beneﬁts of these will have to
be weighed against the risks associated with additional instru-
mentation and manipulation.
The fragility of the aortic wall exposes patients to potentially
fatal retrograde dissection [RTAD] into the coronary vessels orTable 2
Reported cases of endovascular stenting for type A dissection [stent deployed between s
treatment within 14 days].
Author Country Year N¼ 30-day mortality [%] Acute or Chron
Case reports
Ihnken et al.27 USA 2004 1 0 Acute
Zhang et al.28 China 2004 1 0 Chronic
Zimpfer et al.29 Austria 2006 1 0 Chronic
Senay et al.30 Turkey 2007 1 0 Acute
Palma et al.31 Brazil 2007 1 0 Chronic
Metcalfe et al.25 UK 2011 1 0 Acute
Series
Ye et al.26 China 2011 10 10 6 Acute
4 Chronicrupturing into the pericardium. RTAD may also be related to
proximal bare springs of the endografts and overall stiffness of the
endoprosthesis relative to the mobile pulsating ascending aorta.23
These factors are relevant when designing future ascending aortic
devices; making them compliant and ﬂexible to interact with the
aortic wall with atraumatic proximal ﬁxation. Operating so close to
the heart exposes the patient to wire and/or device trauma to the
aortic valve or left ventricle. At deployment the tip of the device
must cross the aortic valve and sit in the left ventricle, with
attendant risk of ventricular perforation. Cardiac trauma can be
minimised by delivery systems with enhanced trackability and
conformation, and accurate wire control throughout the procedure.
This issue further highlights the requirement for custom ascending
aortic devices without the long nosecones of traditional thoracic
endoprostheses. Extra stiff wires with atraumatic ﬂoppy tips,
capable of sitting in the left ventricle, will enhance safety at
deployment.
Current Series/Case Reports [Table 2]
The ﬁrst case report of complete endovascular treatment of
TAAD was published in 2004. Infra-renal aortic endovascular cuffs
have generally been used as they are short enough not to cover the
innominate artery, although they are limited by relatively short
delivery systems. This represents an off-licence use, and therefore
should only be used when all alternative options have been
exhausted. Hybrid revascularisation involving supra-aortic
debranching and deployment of a bifurcate device from the right
common carotid artery has also been reported.24 Although inno-
vative and another example of off-license use, this approach is
limited by endograft diameters, conformation, and morphology.
The ﬁrst report utilising a made-for-purpose Zenith ascending
dissection device was published in 2011.25 These devices, speciﬁc to
the ascending aorta, are undergoing proof of concept studies and
offer the ﬁrst glimpse of a robust endovascular solution with broad
applicability [Fig. 2]. All the case reports of endovascular manage-
ment of TAAD describe successful outcome beyond 30-days; none
report any signiﬁcant perioperative morbidity. A more realistic
description of the likely risks of this procedure is described in the
Chinese series of Ye et al. In their series of mixed acute and chronic
ascending dissections they experienced a 20% stroke rate and 10%
30-day mortality.26 This series should however be interpreted
understanding that 2/10 cases required a hybrid, open and endo-
vascular approach, to create safe landing zones.
Future Developments
It is becoming apparent that different aortic pathologies require
diverse stent-graft solutions. Off-licence techniques such as using
aortic cuffs for TAAD are likely to compromise outcomes and are
unlikely to offer a robust solution. Experience with speciﬁcinotubular junction and innominate artery] [ND ¼ Not described, Acute: deﬁned as
ic Conditions for deployment Stent details
ND 40  10 mm Excluder Cuff [WL Gore, USA]
ND 38  70 mm Gianturco Z-stent
Overdrive pacing 46  85 mm custom stent [Jotec, Germany]
ND 46 mm Talent cuff [Medtronic, USA]
Overdrive pacing 38  155 mm custom partially covered stent
Overdrive pacing 34 mm Zenith ascending dissection device
ND Assorted aortic cuffs 32e42  50e80 mm
[2 hybrid procedures]
Figure 2. Images demonstrating custom ascending aortic stent in-situ landing prox-
imal to innominate artery [3 month follow-up scan]. Volume rendered 3D recon-
struction and axial contrast-enhanced CT image.
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iour of these devices in the ascending aorta, and through entering
cases into registries, document their durability and applicability.
Equally, registries should gather data on all cases turned down for
surgical treatment. This would further clarify the demand for an
endovascular solution.
A new generation of lower proﬁle thoracic devices, 16 Fr [Zenith
TX2 low proﬁle, Cook Medical, USA] are set to be launched. This
would permit a left subclavian artery approach to be taken,
reducing the distance between access and disease and facilitating
more precise deployment. Devices need to be more ﬂexible to
negotiate the arch without trauma, but maintain torque control and
allowmillimetre perfect deployment. The TAVI experiencewill help
to advance endovascular solutions in the ascending aorta.Conclusions
Endovascular development may offer a therapeutic modality for
cases of surgically untreatable type A dissection. Proof of concept
studies are in progress using stent-grafts designed speciﬁcally for
the ascending aorta. Vascular surgeons, cardiologists and cardio-
thoracic surgeons should be encouraged to refer patients that are
ineligible for open surgery to endovascular units offering this
technology. It is inevitable that in the future thoracic endovascular
surgeons will become integral to the multidisciplinary team caring
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